Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis
<h4>Background</h4> Opioid-induced constipation (OIC) is one of the most common adverse events of opioid therapy and can severely reduce quality of life (QOL). Naldemedine is the orally available peripheral-acting μ-opioid receptor antagonist approved for OIC treatment. However in daily...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733844/?tool=EBI |
| _version_ | 1811178141171843072 |
|---|---|
| author | Yuko Kanbayashi Mayumi Shimizu Yuichi Ishizuka Shohei Sawa Katsushige Yabe Mayako Uchida |
| author_facet | Yuko Kanbayashi Mayumi Shimizu Yuichi Ishizuka Shohei Sawa Katsushige Yabe Mayako Uchida |
| author_sort | Yuko Kanbayashi |
| collection | DOAJ |
| description | <h4>Background</h4> Opioid-induced constipation (OIC) is one of the most common adverse events of opioid therapy and can severely reduce quality of life (QOL). Naldemedine is the orally available peripheral-acting μ-opioid receptor antagonist approved for OIC treatment. However in daily clinical practice, some cancer patients show insufficient control of OIC even while receiving naldemedine. <h4>Objective</h4> To identify factors associated with non-response to naldemedine in cancer patients. <h4>Methods</h4> This study retrospectively analyzed 127 cancer patients prescribed naldemedine at Seirei Hamamatsu General Hospital in Japan between November 2016 and June 2021. For the regression analysis of factors associated with OIC, variables were extracted manually from electronic medical records. Naldemedine had been prescribed by the attending physician after the presence of OIC had been defined with reference to Rome IV diagnostic criteria. Naldemedine was evaluated as “effective” in cases where the number of defecations increased at least once in the first 3 days after starting naldemedine. Multivariate logistic regression analysis was performed to identify factors associated with non-response to naldemedine. The data used were from the group of patients who received naldemedine in our previous study. <h4>Results</h4> Factors significantly associated with non-response to naldemedine included chemotherapy with taxanes within 1 month of evaluation of naldemedine effect (odds ratio [OR] = 0.063; 95% confidence interval [CI] = 0.007–0.568), and addition of or switching to naldemedine due to insufficient efficacy of prior laxatives (OR = 0.352, 95% CI = 0.129–0.966). <h4>Conclusion</h4> The identification of factors associated with non-response to naldemedine prescribed for OIC may help improve QOL among cancer patients. |
| first_indexed | 2024-04-11T06:14:22Z |
| format | Article |
| id | doaj.art-9ab0fba8ced844f893004be3a09baebe |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-11T06:14:22Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-9ab0fba8ced844f893004be3a09baebe2022-12-22T04:41:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-011712Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysisYuko KanbayashiMayumi ShimizuYuichi IshizukaShohei SawaKatsushige YabeMayako Uchida<h4>Background</h4> Opioid-induced constipation (OIC) is one of the most common adverse events of opioid therapy and can severely reduce quality of life (QOL). Naldemedine is the orally available peripheral-acting μ-opioid receptor antagonist approved for OIC treatment. However in daily clinical practice, some cancer patients show insufficient control of OIC even while receiving naldemedine. <h4>Objective</h4> To identify factors associated with non-response to naldemedine in cancer patients. <h4>Methods</h4> This study retrospectively analyzed 127 cancer patients prescribed naldemedine at Seirei Hamamatsu General Hospital in Japan between November 2016 and June 2021. For the regression analysis of factors associated with OIC, variables were extracted manually from electronic medical records. Naldemedine had been prescribed by the attending physician after the presence of OIC had been defined with reference to Rome IV diagnostic criteria. Naldemedine was evaluated as “effective” in cases where the number of defecations increased at least once in the first 3 days after starting naldemedine. Multivariate logistic regression analysis was performed to identify factors associated with non-response to naldemedine. The data used were from the group of patients who received naldemedine in our previous study. <h4>Results</h4> Factors significantly associated with non-response to naldemedine included chemotherapy with taxanes within 1 month of evaluation of naldemedine effect (odds ratio [OR] = 0.063; 95% confidence interval [CI] = 0.007–0.568), and addition of or switching to naldemedine due to insufficient efficacy of prior laxatives (OR = 0.352, 95% CI = 0.129–0.966). <h4>Conclusion</h4> The identification of factors associated with non-response to naldemedine prescribed for OIC may help improve QOL among cancer patients.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733844/?tool=EBI |
| spellingShingle | Yuko Kanbayashi Mayumi Shimizu Yuichi Ishizuka Shohei Sawa Katsushige Yabe Mayako Uchida Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis PLoS ONE |
| title | Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis |
| title_full | Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis |
| title_fullStr | Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis |
| title_full_unstemmed | Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis |
| title_short | Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis |
| title_sort | factors associated with non response to naldemedine for opioid induced constipation in cancer patients a subgroup analysis |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733844/?tool=EBI |
| work_keys_str_mv | AT yukokanbayashi factorsassociatedwithnonresponsetonaldemedineforopioidinducedconstipationincancerpatientsasubgroupanalysis AT mayumishimizu factorsassociatedwithnonresponsetonaldemedineforopioidinducedconstipationincancerpatientsasubgroupanalysis AT yuichiishizuka factorsassociatedwithnonresponsetonaldemedineforopioidinducedconstipationincancerpatientsasubgroupanalysis AT shoheisawa factorsassociatedwithnonresponsetonaldemedineforopioidinducedconstipationincancerpatientsasubgroupanalysis AT katsushigeyabe factorsassociatedwithnonresponsetonaldemedineforopioidinducedconstipationincancerpatientsasubgroupanalysis AT mayakouchida factorsassociatedwithnonresponsetonaldemedineforopioidinducedconstipationincancerpatientsasubgroupanalysis |